|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Up to date only one IFNα subtype (IFNα2) is being used in clinical treatment against chronic virus infections, however its therapeutic success rate is rather limited, especially during Human Immunodeficiency Virus (HIV) infection.
|
29475588 |
2018 |
|
Virus Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection.
|
27153246 |
2017 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A number of recombinant protein therapeutic products, such as filgrastim (methionyl granulocyte colony stimulating factor [Met-GCSF] used to boost the immune system in chemotherapy treated cancer patients), and interferon alpha-2 (used for the treatment of various viral infections), have been chemically modified with the addition of a polyethylene glycol (PEG) chain.
|
28254519 |
2017 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that IFN-1ant may be a therapeutic candidate for the treatment of specific viral infections without inducing the immunomodulatory and antiproliferative functions of wild-type IFN.
|
24866020 |
2014 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A 34-year-old white woman with chronic hepatitis C virus infection who was treated with pegylated interferon α-2a and ribavirin, developed Grave's disease and autoimmune hepatitis (AIH) at 32 and 44 weeks, respectively, following initiation of the therapy.
|
21912063 |
2012 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
|
22098185 |
2012 |
|
Virus Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
|
11106097 |
2000 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
|
10534516 |
1999 |
|
Virus Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection.
|
9097267 |
1997 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Response to a 1-yr course of interferon-alpha 2b was assessed in 18 patients with chronic hepatitis C virus infection in relation to clinical, biochemical and histological parameters and to the presence or absence of hepatitis C virus RNA and the presumed replicative form of the virus (negative-strand hepatitis C virus RNA) in serum, liver and peripheral blood mononuclear cells.
|
7982638 |
1994 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Two such hybrid cell lines responded to IFNs alpha 2, -alpha B and -beta by induction of 2'-5' oligoadenylate synthetase and resistance to viral infection.
|
8188689 |
1994 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response.
|
8188163 |
1994 |